Loading...

Anbio Biotechnology Class A Ordinary Shares

NNNNNASDAQ
Healthcare
Medical - Instruments & Supplies
$50.62
$0.91(1.83%)

Anbio Biotechnology Class A Ordinary Shares (NNNN) Company Profile & Overview

Explore Anbio Biotechnology Class A Ordinary Shares’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Anbio Biotechnology Class A Ordinary Shares (NNNN) Company Profile & Overview

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

SectorHealthcare
IndustryMedical - Instruments & Supplies
CEOMichael Lau

Contact Information

49 16 0962 47281
Wilhelm Gutbrod Str 21B, Frankfurt am Main, 60437

Company Facts

27 Employees
IPO DateFeb 19, 2025
CountryDE
Actively Trading

Frequently Asked Questions

;